Figure 8. Untargeted metabolomics analysis of PfA-M17-HAglmS and Pf3D7 parasites treated with ± GlcN and of Pf3D7 parasites treated with 3 from experiment 1.

(A) Principal component analysis (PCA) of parasites (PfA-M17-HAglmS and Pf3D7) treated with ± GlcN and 3 or DMSO control. Scores plot show principal components one and two, data points indicate individual sample replicates within each condition and the shaded area denotes 95% confidence interval. (B) Heatmap showing the average fold change for all putative metabolites for the three treatment conditions of Pf3D7+ GlcN versus WT, Pf3D7 +compound 3 versus WT, and PfA-M17HAglmS + GlcN versus PfA-M17HAglmS. For PfA-M17HAglmS + GlcN versus PfA-M17HAglmS, the fold change values have been ordered from highest to lowest. Values represent the average of three technical replicates, red, blue, and yellow indicates increase, decrease and no change, respectively, in the fold change of putative metabolites identified.

Figure 8—figure supplement 1. Untargeted metabolomics analysis of PfA-M17-HAglmS and Pf3D7 parasites treated with ±GlcN from experiment 2.

(A) Principal component analysis (PCA) of parasites (PfA-M17-HAglmS and Pf3D7) treated with ± GlcN. Scores plot show principal components one and two, data points indicate individual sample replicates within each condition and the shaded area denotes 95% confidence interval. (B) Heatmap analysis of peak intensities of all putative metabolites for each condition. Data is shown from three technical replicates, red, blue and yellow indicates increase, decrease and no change respectively in the relative abundance of putative metabolites identified.

Figure 8—figure supplement 2. Untargeted metabolomics analysis of Pf3D7 parasites treated with 3 and DMSO control from experiment 3.

(A) Principal component analysis (PCA) of parasites Pf3D7 treated with 3 and DMSO control. Scores plot show principal components one and two, data points indicate individual sample replicates within each condition and the shaded area denotes 95% confidence interval. (B) Heatmap analysis of peak intensities of all putative metabolites for each condition. Data is shown from four to nine biological replicates, red, blue, and yellow indicates increase, decrease and no change respectively in the relative abundance of putative metabolites identified.

Figure 8—figure supplement 3. Targeted analysis of all common peptides identified from experiment 1, 2 and 3.

(A) Principal component analysis (PCA) of common peptides identified across three experiments for parasites (PfA-M17-HAglmS and Pf3D7) treated with +/-GlcN and 3 or DMSO control. Scores plot show principal components one and two, data points indicate individual sample replicates within each condition and the shaded area denotes 95% confidence interval. (B) Hierarchical clustering of the common peptides identified across the three independent experiments. Vertical clustering displays similarities between sample groups, while horizontal clusters reveal the relative abundances (median normalized) of common identified peptides (149). The color scale bar represents log₂ (mean-centred and divided by the standard deviation of each variable) intensity values.